Article
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.
The Lancet. Oncology - 1 Nov 2020
Morschhauser Franck, Tilly Hervé, Chaidos Aristeidis, McKay Pamela, Phillips Tycel, Assouline Sarit, Batlevi Connie Lee, Campbell Phillip, Ribrag Vincent, Damaj Gandhi Laurent, Dickinson Michael, Jurczak Wojciech, Kazmierczak Maciej, Opat Stephen, Radford John, Schmitt Anna, Yang Jay, Whalen Jennifer, Agarwal Shefali, Adib Deyaa, Salles Gilles
Abstract excerpt
BACKGROUND: Activating mutations of EZH2, an epigenetic regulator, are present in approximately 20% of patients with follicular lymphoma. We investigated the activity and safety of tazemetostat, a first-in-class, oral EZH2 inhibitor, in patients with follicular lymphoma. METHODS: This study was an open-label, single-arm, phase 2 trial done at 38 clinics or hospitals in France, the UK, Australia, Canada, Poland,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.